These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 16739255)
21. [Mechanism of action of antileukemic agents in leukemia chemotherapy]. Nakamura T Rinsho Ketsueki; 1996 May; 37(5):380-91. PubMed ID: 8691581 [No Abstract] [Full Text] [Related]
22. [Treatment of acute leukemia]. Jacquillat C; Weil M Rev Med Suisse Romande; 1969 Jan; 89(1):15-41. PubMed ID: 5771844 [No Abstract] [Full Text] [Related]
23. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise? Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470 [No Abstract] [Full Text] [Related]
24. Troxacitabine in patients with refractory leukemia. Karrison T; Ratain M J Clin Oncol; 2002 Aug; 20(15):3356; author reply 3356-7. PubMed ID: 12149312 [No Abstract] [Full Text] [Related]
25. [Prognosis in acute non-lymphoblastic leukemia]. Sierra J; Rozman C Med Clin (Barc); 1987 Jun; 89(4):150-2. PubMed ID: 3306191 [No Abstract] [Full Text] [Related]
26. The uncontrolled clinical trial: scientific, ethical, and practical reasons for being. Saccà L Intern Emerg Med; 2010 Jun; 5(3):201-4. PubMed ID: 20169422 [TBL] [Abstract][Full Text] [Related]
27. [Acute leukemia results of treatment at a provincial hospital]. Magnusson S; Möller BH Lakartidningen; 1980 Oct; 77(40):3516-7. PubMed ID: 7453351 [No Abstract] [Full Text] [Related]
28. Chemotherapy of acute leukemia from the viewpoint of the action mechanism of antitumor agents. Nakamura T Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1022-33. PubMed ID: 7331684 [No Abstract] [Full Text] [Related]
29. Principles of chemotherapy of acute leukaemia. Holland JF Triangle; 1967; 8(2):53-64. PubMed ID: 5602880 [No Abstract] [Full Text] [Related]
30. Optimising the design of phase II oncology trials: the importance of randomisation. Ratain MJ; Sargent DJ Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773 [TBL] [Abstract][Full Text] [Related]
32. Newer phase II trial designs gaining ground. Benowitz S J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467 [No Abstract] [Full Text] [Related]
33. [Acute leukemia in pregnancy]. Med Clin (Barc); 1987 Sep; 89(8):350-1. PubMed ID: 3695727 [No Abstract] [Full Text] [Related]
34. Descriptions in the peer-reviewed literature of the results of phase 2 chemotherapy trials involving gynecologic malignancies: a call for greater objectivity. Markman M Gynecol Oncol; 2006 Sep; 102(3):419-20. PubMed ID: 16814850 [No Abstract] [Full Text] [Related]
35. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer. Kell J Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879 [TBL] [Abstract][Full Text] [Related]
36. Reactive oxygen species may have antitumor activity in metastatic melanoma. Tuma RS J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075 [No Abstract] [Full Text] [Related]
37. A strategic framework for novel drug development in multiple myeloma. Anderson KC; Hannah AL; Pazdur R; Farrell AT Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022 [No Abstract] [Full Text] [Related]